We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
Cap. Flow
+$198M
Cap. Flow %
32.7%
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$118M
2
TNGX icon
Tango Therapeutics
TNGX
+$67.4M
3
RVMD icon
Revolution Medicines
RVMD
+$23.6M
4
PHVS icon
Pharvaris
PHVS
+$18.2M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.1M

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$7.49M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.63M
3
PCVX icon
Vaxcyte
PCVX
+$4.27M
4
SLNO
Soleno Therapeutics
SLNO
+$3.88M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
76
BioCryst Pharmaceuticals
BCRX
$2.2B
$510K 0.08%
51,024
-51,469
-50% -$465K
DRUG
77
Bright Minds Biosciences
DRUG
$508M
$449K 0.07%
6,395
– –
PRTA icon
78
Prothena Corp
PRTA
$426M
$424K 0.07%
43,300
– –
GLUE icon
79
Monte Rosa Therapeutics
GLUE
$1B
$407K 0.07%
16,800
-5,730
-25% -$108K
OLMA icon
80
Olema Pharmaceuticals
OLMA
$766M
$394K 0.07%
+31,476
New +$422K
MIST icon
81
Milestone Pharmaceuticals
MIST
$98.2M
$362K 0.06%
270,233
-63,100
-19% -$101K
ENTX icon
82
Entera Bio
ENTX
$476M
$339K 0.06%
191,354
-14,188
-7% -$17.7K
CUE icon
83
Cue Biopharma
CUE
$228M
$338K 0.06%
+10,702
New +$242K
MBX
84
MBX Biosciences
MBX
$2.58B
$331K 0.05%
+6,000
New +$210K
BEAM icon
85
Beam Therapeutics
BEAM
$2.51B
$302K 0.05%
8,804
– –
AZN icon
86
AstraZeneca
AZN
$258B
$265K 0.04%
+1,400
New +$263K
AMLX icon
87
Amylyx Pharmaceuticals
AMLX
$3.76B
$261K 0.04%
14,540
-2,131
-13% -$33K
STOK icon
88
Stoke Therapeutics
STOK
$1.6B
$255K 0.04%
+7,745
New +$249K
VKTX icon
89
Viking Therapeutics
VKTX
$4.15B
$252K 0.04%
+7,404
New +$239K
LPCN icon
90
Lipocine
LPCN
$17.3M
$202K 0.03%
78,842
-46,100
-37% -$111K
CRBP icon
91
Corbus Pharmaceuticals
CRBP
$138M
$201K 0.03%
21,432
-64,255
-75% -$608K
PMN icon
92
ProMIS Neurosciences
PMN
$101M
$139K 0.02%
10,600
– –
WVE icon
93
Wave Life Sciences
WVE
$745M
$99.8K 0.02%
+19,048
New +$126K
PMVP icon
94
PMV Pharmaceuticals
PMVP
$71.1M
$71.8K 0.01%
53,569
-9,929
-16% -$12.7K
FULC icon
95
Fulcrum Therapeutics
FULC
$285M
$66.2K 0.01%
18,089
-20,011
-53% -$122K
QURE icon
96
uniQure
QURE
$2.65B
$15.3K ﹤0.01%
+338
New +$8.85K
APGE
97
DELISTED
Apogee Therapeutics
APGE
– –
-1,969
Closed -$166K
CGEM icon
98
Cullinan Oncology
CGEM
$953M
– –
-1,844
Closed -$26.2K
CMPS
99
Compass Pathways
CMPS
$1.81B
– –
-158,021
Closed -$874K
CNTX icon
100
Context Therapeutics
CNTX
$31.8M
– –
-190,785
Closed -$500K
1 2 3
4
5

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.

  • Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
  • Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
  • Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
  • Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
  • Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
  • Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
  • Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.